Bright Minds Biosciences (DRUG) Receivables - Other (2020 - 2025)

Bright Minds Biosciences has reported Receivables - Other for 6 years, with the latest figure at $113645.2 in Q2 2025.

• For the quarter ending Q2 2025, Receivables - Other changed N/A year-over-year to $113645.2; the trailing twelve-month figure through Jun 2025 stood at $113645.2 (changed N/A YoY), and the FY2022 full-year result was $31636.7, up 18.23% from the prior year.
• Receivables - Other for Q2 2025 stood at $113645.2, down from $123994.7 in the prior quarter.
• The five-year high for Receivables - Other was $401891.4 in Q1 2024, with the low at -$27402.8 in Q2 2021.
• Historically, Receivables - Other has averaged $73543.6 across 5 years, with a median of $30618.7 in 2023.
• Annual changes were most pronounced in 2021 — Receivables - Other jumped 3465.84% — and 2025, when it tumbled 69.15%.
• Bright Minds Biosciences' Receivables - Other stood at -$26722.7 in 2021, then surged by 213.75% to $30397.1 in 2022, then advanced by 1.05% to $30716.9 in 2023, then soared by 1208.37% to $401891.4 in 2024, then plunged by 71.72% to $113645.2 in 2025.
• The last three Receivables - Other figures came in at $113645.2 (Q2 2025), $123994.7 (Q1 2025), and $401891.4 (Q1 2024), per Business Quant data.